INHIBITORS OF MACROPHAGES IN NEOPLASIA RELATIONSHIP

在接下来的一年里，我们将开始研究，以确定是否单克隆 抗p15 E可用于预防或减缓腹膜内或腹膜外肿瘤的生长， 皮下注射肿瘤细胞或延长存活时间 肿瘤动物 三株产生单克隆抗体的杂交瘤细胞系 针对逆转录病毒p15E上不同表位的抗体目前正在 用于从所述抗体中产生足够大量的抗体。 用于这些实验的培养物上清液。 小鼠将接受以下处理： 完整IgG或F（ab '）2 抗体的片段。 控制 小鼠将注射相同量的纯化F（ab '）IgG2 与所用单克隆抗p15 E同种型相同的片段。 的 抗体将单独使用和以各种组合使用。 小鼠将 在肿瘤细胞接种之前和之后定期注射。 抗p15 E抗体的循环水平，如果可能的话，p15 E本身将是 在实验过程中进行监控。 我们将继续我们的研究，以确定循环p15 E水平， 以及p15 E水平是否与肿瘤相关 生长或转移。 我们将继续使用我们的竞争ELISA检测 但在明年，我们将努力 确定我们的最低灵敏度水平将是使用这个分析。 此外，利用重组DNA技术获得的p15 E， 尝试开发新的高灵敏度的p15 E RIA和EIA检测方法。 使用对应于p15 E蛋白部分的合成肽， 例如我们最近发现与包膜同源区域 蛋白gp21 E，我们将确定p15 E介导的HTLV的机制， 免疫抑制 我们还将使用这种合成肽来生产 针对p15E蛋白的特定区域的特异性抗体。 （IS）

During the next year we will begin studies to determine if monoclonal anti-p15E can be used to prevent or slow the growth of intraperitoneally or subcutaneously injected tumor cells or to prolong the survival of tumor-bearing animals. Three hybridoma cell lines producing monoclonal antibodies to different epitopes on retroviral p15E are currently being used to produce sufficiently large quantities of antibodies from the culture supernatants for these experiments. Mice will be treated with either intact IgG or the F(ab')2 fragments of the antibodies. Control mice will be injected with the same amounts of purified IgG of F(ab')2 fragments of the same isotype as the monoclonal anti-p15E used. The antibodies will be used singularly and in various combinations. Mice will be injected prior to and at regular intervals after tumor cell inoculation. Circulating levels of anti-p15E and, if possible, p15E itself will be monitored during the course of the experiments. We will continue our studies to determine circulating p15E levels in tumor-bearing mice and whether the levels of p15E correlate with tumor growth or metastasis. We will continue to use our competition ELISA assay to make these determinations, but during the next year we will attempt to determine what our loweat level of sensitivity will be using this assay. In addition, using p15E obtained by recombinant DNA technology we will attempt to develop new highly sensitive RIA and EIA assays for p15E. Using synthetic peptides corresponding to portions of the p15E protein, such as that region we have recently shown to be homologous to the envelope protein gp21E of HTLV, we will determine the mechanisms of p15E-mediated immunosuppression. We will also use such synthetic peptides to produce specific antibodies to defined regions of the p15E protein. (IS)